Lupin in its press note to the exchanges informed that the United States Food and Drug Administration (USFDA) issued two observations for its Goa manufacturing facility.
"The observations are procedural in nature and the company is confident of addressing them satisfactorily," the company said in a press note after markets hours to the exchanges on Friday.
Observations have been issued after the completion of the inspection. The inspection was carried out from January 28 to February 8, the company added.
Lupin Ltd's share price ended at Rs829, down by Rs1.4 or 0.17%, from its previous close of Rs830.40 on the BSE.
The scrip opened at Rs830.40 and touched a high and low of Rs848 and Rs829, respectively. A total of, 23,396 (NSE+BSE) shares have traded on the counter. The current market cap of the company is Rs37,571.59cr.